Industry
Biotechnology
Passage Bio, Inc., a genetic medicines company, develops transformative therapies for central nervous system diseases. It develops PBGM01, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GLB1 gene encoding lysosomal acid beta-galactosidase for infantile GM1; PBFT02, which utilizes an AAV1 capsid to deliver to the brain a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD-GRN; and PBKR03, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company also develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and PBCM06 for the treatment of Charcot-Marie-Tooth Type 2A. Passage Bio, Inc. has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. The company was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.
Loading...
Open
0.75
Mkt cap
45M
Volume
415K
High
0.75
P/E Ratio
-0.62
52-wk high
1.79
Low
0.66
Div yield
N/A
52-wk low
0.45
Portfolio Pulse from
November 06, 2024 | 12:15 pm
Portfolio Pulse from Benzinga Insights
October 25, 2024 | 12:08 pm
Portfolio Pulse from Benzinga Insights
October 25, 2024 | 12:07 pm
Portfolio Pulse from Benzinga Newsdesk
October 24, 2024 | 6:01 pm
Portfolio Pulse from Benzinga Newsdesk
October 24, 2024 | 11:12 am
Portfolio Pulse from Benzinga Newsdesk
September 16, 2024 | 11:05 am
Portfolio Pulse from Benzinga Newsdesk
September 03, 2024 | 12:24 pm
Portfolio Pulse from Benzinga Newsdesk
September 03, 2024 | 12:07 pm
Portfolio Pulse from Benzinga Insights
September 02, 2024 | 8:31 pm
Portfolio Pulse from charles@benzinga.com
August 01, 2024 | 11:13 am
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.